[Anti-counterfeit activities of pharmaceutical companies in Japan: for patient safety].
Global spread of counterfeit medicines is an imminent threat for the patients' safety. Although major targets of counterfeits are still erectile dysfunction (ED) drugs in the industrialized countries, including Japan, anti-cancer agents and some medicines for metabolic syndromes are also being counterfeited and circulated to the market mainly through the Internet. Due to the global expansion of the business, pharmaceutical companies based in Japan are suffering from the damage of counterfeits, illegal sales including diversion, and thefts, which have never been experienced in the conventional domestic market. We, pharmaceutical companies, must be responsible for the prevention of the prevalence because our mission is to deliver effective and safe medicine to patients. For this end, we are taking necessary actions including, 1. Forestalling counterfeit, falsification and illicit trade: Measures to prevent counterfeiting are taken by introducing anti-counterfeit technologies to the packaging and tablets on a risk basis. It is also important to establish supply chain security on a global scale. 2. Finding out counterfeits and cooperating crackdown: We are conducting market and internet surveillances when high risk products are sold in high risk markets. The outcome of the criminal investigation is reported to authorities and police if necessary. 3. Conducting educational campaign to medical staff or patients: For example, four companies which manufacture and sell ED drug in Japan are collaboratively continuing activities to raise the awareness of the danger of Internet purchase. To deliver effective and safe medicines stably and globally, pharmaceutical companies extend comprehensive measures against counterfeit and illicit trading.
Global Quality Assurance Department, Takeda Pharmaceutical Company Limited.
Ken-ichi
K
Shofuda
Katsumi
K
Aragane
Yasutaka
Y
Igari
Kinya
K
Matsumoto
Kazuya
K
Ito
D058110:Counterfeit Drugs; D003415:Crime / Q000517:prevention & control*; D004345:Drug Industry; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D014943:Global Health; D006801:Humans; D020407:Internet; D007564:Japan; D061214:Patient Safety
D058110:Counterfeit Drugs